Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience

Basit Öğe Kaydı
dc.authoridKivanc Altunay, Ilknur/0000-0002-1354-7123
dc.authoridDogan, Sinan/0000-0001-5448-9671
dc.authorwosidAltunay, Ilknur Kivanc/E-7490-2016
dc.contributor.authorGönülal, Melis
dc.contributor.authorAltunay, İlknur Kivanç
dc.contributor.authorDoğan, Sinan
dc.contributor.authorTürkmen, Meltem
dc.contributor.authorBalcı, Didem Didar
dc.contributor.authorÖztürkcan, Serap
dc.date.accessioned2023-03-22T19:47:31Z
dc.date.available2023-03-22T19:47:31Z
dc.date.issued2022
dc.departmentBelirleneceken_US
dc.description.abstractReal-life data about any particular treatment is very helpful for clinicians, particularly when managing a chronic disease such as psoriasis. In our study, we aimed to reflect our clinical experience during 48 weeks with an IL-17 antagonist ixekizumab. This study was designed as a retrospective multi-center study. Four tertiary referral centers participated into the study. The patients who did not present to the clinics for 3rd month follow-up were excluded. Data including gender, age, weight, type of psoriasis, additional sites on the body, disease duration, previous treatments, duration of medication of ixekizumab, psoriasis area and severity index scores, previous treatments, and comorbidities, the reasons for drug discontinuation, adverse effects and the patients' naive or non-naive status were retrieved from electronic patient folders. Although 267 patients met the inclusion criteria, 28 patients were excluded since they did not present to the clinic for 3rd month follow-up so 239 cases were included mmune research. We determined significant correlations between naive and non-naive cases about getting PASI 75 and PASI 90 responses for all cases (p = 0.005 and p = 0.028, respectively) and between comorbid and non-comorbid cases about getting PASI 90 and PASI 100 responses for all cases (p = 0.021 and p = 0.029, respectively). When we investigate as female and male patients separately, non-comorbid female cases can achieve PASI 100 response significantly easier than comorbid female patients (p = 0.019). Clinicians can use ixekizumab safely mmune treatment of their patients with psoriasis and get PASI 75-90-100 responses quickly. Ixekizumab is more effective for naive cases but it may also be a treatment option for biologic experienced patients. The ratio of PASI 75-90-100 responses are better in non-comorbid cases than comorbid patients nevertheless ixekizumab is a quite effective agent mmune treatment of comorbid cases.en_US
dc.identifier.doi10.1111/dth.15955
dc.identifier.issn1396-0296
dc.identifier.issn1529-8019
dc.identifier.issue12en_US
dc.identifier.pmid36271759en_US
dc.identifier.scopus2-s2.0-85141129862en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1111/dth.15955
dc.identifier.urihttps://hdl.handle.net/20.500.14034/745
dc.identifier.volume35en_US
dc.identifier.wosWOS:000876318700001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Hindawien_US
dc.relation.journalDermatologic Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectanti-IL-17en_US
dc.subjectixekizumaben_US
dc.subjectpsoriasisen_US
dc.titleIxekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Ixekizumab for the treatment of the patients with moderate tosevere plaque psoriasis.pdf
Boyut:
1.06 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin / Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu